Lantern Pharma (LTRN) announced the presentation of clinical data from its ongoing Phase 1 trial of LP-284 at the 25th Annual Lymphoma, Leukemia & ...

Success with a smart VF is less about the screens and more about how people interact with the data and each other.

Leading clinicians, researchers & pharmaceutical innovators gathered to discuss the future of cancer treatment.

Pharma’s finally catching up: real-time data is helping teams move faster, stay compliant and deliver better care where it ...

However, if pharma manufacturers aren’t using RWD in a strategic way, they’ll miss out on its full potential. And with that, they risk costly inefficiencies, slowing down their time to bring therapies ...

In an industry where speed and precision can directly affect patient outcomes, pharma companies are under pressure to ...

BERLIN--(BUSINESS WIRE)--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor ...

Tonix Pharmaceuticals (TNXP) presented data on Tonmya, which was investigated as TNX-102 SL, at the 2025 American College of Rheumatology ...

Findings complement previously announced results in triple-negative breast cancer (TNBC) and prostate cancer models, highlighting Telomir-1’s consistent impact on cancer cell survival pathways. MIAMI, ...

Terns Pharmaceuticals' trial data from its oral GLP-1 treatment for obesity missed a high threshold for efficacy, safety and tolerability. The biopharmaceutical company said Tuesday it will not ...

Recursion Pharmaceuticals shows high cash burn, limited efficacy data, and unproven platform validation. Check out why RXRX ...

Mistargeted and irrelevant ads plague the TV viewing experience. Pharma brands struggle with targeting and measurement because patient data is highly regulated. A web of national laws, namely HIPAA, ...